AbbVie Aktie
WKN DE: A1J84E / ISIN: US00287Y1091
28.09.2024 08:43:01
|
AbbVie Submits BLA To FDA For Telisotuzumab Vedotin In Previously Treated Non-Small Cell Lung Cancer
(RTTNews) - AbbVie (ABBV) announced submission of a Biologics License Application or BLA to the U.S. Food and Drug Administration for accelerated approval of telisotuzumab vedotin (Teliso-V) in adult patients with previously treated, locally advanced or metastatic epidermal growth factor receptor or EGFR wild type, nonsquamous non-small cell lung cancer or NSCLC with c-Met protein overexpression.
The BLA submission is supported by data from Phase 2 LUMINOSITY trial (Study M14-239), an ongoing study designed to characterize the safety and efficacy of Teliso-V in c-Met overexpressing NSCLC populations.
Teliso-V was granted Breakthrough Therapy Designation by the FDA in December 2021.
For More Such Health News, visit rttnews.com.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu AbbVie Incmehr Nachrichten
Analysen zu AbbVie Incmehr Analysen
Aktien in diesem Artikel
AbbVie Inc | 170,34 | -7,14% |
|